The National Institute for Health and Care Excellence (NICE) has issued a Final Assessment Decision (FAD) recommending Dupixent.® (Dupilumab), as an additional maintenance therapy for severe asthma.[1*]
NICE FAD is based on a subset of patients participating in the LIBERTY ASTHMAQUEST clinical trial.
Dupilumab acts on the type 2 immune response, which is thought to be the leading driver of severe asthma. Dupilumab differs from many existing treatments because it works by weakening two major factors in the inflammatory process: interleukin-4 and interleukin-13. Patients with severe asthma with type 2 inflammation have been shown to reduce severe asthma attacks by up to 67% compared to placebo and nearly 50% reduction in hospitalization / A & E visits compared to placebo.
In addition to reducing asthma attacks and hospitalization / A & E visits, in clinical trials, dupilumab improved lung function (FEV1) in patients with type 2 inflammation by up to 250 ml compared to placebo. In addition, dupilumab eliminated the need for oral corticosteroids in 52% (51 patients) of OCS-dependent patients with type 2 inflammation (compared to 29% (27 patients) of placebo. ).
Professor Ian Pavord, Professor of Respiratory Medicine, Respiratory Medicine Unit, Oxford Respiratory NIHRBRC, University of Oxford, said: It is difficult to lead a normal life. Uncontrollable asthma with drugs and too often a severe asthma attack can be life-threatening. It is especially important to provide patients with new treatment options during an ongoing pandemic, as people with severe asthma feel particularly vulnerable. Biological treatments such as dupilumab that target one of the leading root causes of severe asthma can change the outcome of people with severe asthma. “
 Nice, (2021). Final evaluation decision. Dupilumab for the treatment of severe asthma with type 2 inflammation. available: [insert link].. Last access date: 2021.
 Mukherjee M, Stoddart A, Gupta RP et al. Analysis of an independent, linked national database of asthma epidemiology, medical care, social burdens and costs in the United Kingdom and its member countries. BMC Med 14, 113 (2016). https://doi.org/10.1186/s12916-016-0657-8
 Asthma UK, (2018). Sliding through the net: the reality faced by patients with difficult and severe asthma. It is available at https://www.asthma.org.uk/6fc29048/globalassets/get-involved/external-affairs-campaigns/publications/severe-asthma-report/auk-severe-asthma-gh-final.pdf. Last access date: October 2021.
NICE recommends new treatments for asthma in the UK
Source link NICE recommends new treatments for asthma in the UK